Pharmacy multidisciplinary stewardship program for high-risk patients prescribed opioids in an academic clinic.

OBJECTIVE: To assess observation of the Centers for Disease Control (CDC) Guideline for prescribing opioids for chronic pain within a Pharmacy Controlled Substance Clinic (PCSC) compared to usual care by resident physicians in a Primary Care Internal Medicine (IM) clinic. DESIGN: Single-center, retrospective cohort. SETTING: IM clinic within a large, academic medical center. PARTICIPANTS: Patients receiving stable opioid prescriptions for management of chronic nonmalignant pain (CNCP) were screened. Exclusions included age < 18 years old, aberrant opioid use behaviors, or malignancy-related pain. Both cohorts included 100 eligible patients. INTERVENTIONS: Within the PCSC, a pharmacy team provided assistance to resident physicians monitoring patients receiving opioid medications. MAIN OUTCOME MEASURES: The primary outcome was application of CDC guidelines: creation of an annual patient provider agreement (PPA); annual urine drug screen (UDS); quarterly review of a prescription drug monitoring program (CURES); and documentation of quarterly evaluation of opioid use. Secondary outcomes included risk factors for opioid-related harms. RESULTS: Respective measures from the control versus the intervention group demonstrated: PPA creation in 28 percent (n = 28) versus 100 percent (n = 100) (p < 0.001); UDS obtained in 59.2 percent (n = 58) versus 90.6 percent (n = 87) (p < 0.001); quarterly CURES review in 26 percent (n = 26) versus 70 percent (n = 70) (p < 0.001); and quarterly evaluation of opioid use in 26 percent (n = 26) versus 37 percent (n = 37) (p = 0.10). CONCLUSIONS: Pharmacy-led monitoring of patients prescribed opioids for CNCP in an academic resident clinic improves implementation of CDC guidelines. Similar multidisciplinary team integration may improve opioid prescribing safety in academic primary care settings.

Pharmacist-led medication management program within a patient-centered medical home.

PURPOSE: The impact of a clinical pharmacist-led medication management program (MMP) within a patient-centered medical home (PCMH) was evaluated. METHODS: This retrospective analysis included patients in Sutter Health's electronic health records who (1) were seen by the MMP clinical pharmacist within the PCMH (MMP cohort), (2) were within the PCMH but were not referred to the MMP pharmacist (PCMH cohort), or (3) received usual care at two non-PCMH primary care clinics (usual care cohort). Patients were matched on their propensity for receiving medication management. The primary outcome measure was healthcare resource use (i.e., ambulatory care visits, emergency department [ED] visits, and hospitalizations). RESULTS: MMP patients had a higher percentage of ambulatory care visits relative to PCMH patients (p = 0.004) but a lower rate of hospitalizations (p = 0.003). The MMP group had a lower frequency of hospitalizations (p < 0.001) and ED visits (p = 0.014) relative to patients in the usual care group. No differences in healthcare resource use were observed between the PCMH and usual care cohorts. Glycosylated hemoglobin, blood pressure, or low-density-lipoprotein cholesterol at goal did not significantly differ among the three cohorts. CONCLUSION: Patients in a pharmacist-led MMP had a significantly higher estimated rate of ambulatory care visits but a lower rate of hospitalizations than did patients who attended the same clinic but were not in the MMP. MMP patients had a similar rate of ambulatory care visits but significantly lower rates of hospitalizations and ED visits than patients receiving usual care.

Multivariate analysis of factors associated with persistent colesevelam treatment among patients with hypercholesterolemia.

BACKGROUND: Persistent treatment with lipid-lowering therapies is important for achieving optimal clinical outcomes. To date, no study has evaluated the real-world use of colesevelam and the factors associated with persistent colesevelam treatment. OBJECTIVE: The primary objective of this study was to examine patient demographic and characteristics associated with persistent colesevelam treatment in real-world clinical practice. METHODS: In this retrospective cohort study, adult patients with hypercholesterolemia, an initial order for colesevelam between January 2004 and December 2011, a low-density lipoprotein cholesterol (LDL-C) value ≤ 3 months from the initial order date (baseline), and ≥ 12 months of follow-up were identified through electronic health records. Persistent treatment was defined as no medication order gap >30 days during a 12-month period. Multivariate logistic regression was performed to assess factors associated with persistent treatment. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. A P value <.05 was considered statistically significant. RESULTS: A total of 971 patients met eligibility criteria. Forty-nine percent of patients had ≥ 12 months of persistent treatment. Multivariate analysis showed that female sex (OR = 0.69; 95% CI = 0.53, 0.90; P = .004) was associated with lesser odds of persistence, whereas baseline LDL-C at goal (1.39; 1.06, 1.82; P = .015) and concomitant use of the intestinal cholesterol absorption inhibitor ezetimibe (1.64; 1.18, 2.28; P = .003) were associated with greater odds of persistence. CONCLUSIONS: This study identified several patient demographic and characteristics associated with persistent colesevelam treatment that may help develop strategies to improve treatment persistence and optimize clinical outcomes.

Colesevelam in the treatment of hypercholesterolemia and hyperglycemia: a retrospective analysis from an ambulatory care medical network.

OBJECTIVE: To examine outcomes associated with colesevelam treatment among patients with hypercholesterolemia in real-world clinical practice. METHODS: This analysis was conducted as a retrospective, observational cohort study in an ambulatory-care medical network in Northern California. Patients with orders for colesevelam were identified in the electronic health record between January 2004 and December 2011. The date of the first order during the study period was designated the index date. Patients were evaluated for the following eligibility criteria: a diagnosis of hypercholesterolemia, ≥18 years of age at index date, baseline laboratory values ≤3 months before the index date, ≥12 months of treatment and follow-up, and no prior orders for colesevelam ≤12 months before the index date. Patients who were pregnant during the study period were excluded. Changes in LDL-C and percentage of patients at LDL-C goal were examined. Among patients with diabetes mellitus (DM), changes in glycated hemoglobin (HBA1C) and percentage of patients at HBA1C goal were also examined. RESULTS: Overall, 468 and 181 patients with hypercholesterolemia met the predefined inclusion criteria with treatment and follow-up through 12 and 24 months, respectively. LDL-C decreased significantly from baseline by a mean of 11.4 mg/dL and 15.7 mg/dL (P < 0.0001, for each) at 12 and 24 months, respectively, and the percentages of patients at LDL-C goal increased by 13.9% and 21.0%. Among patients with DM and a baseline HBA1C ≥8%, 113 and 39 had treatment and follow-up through 12 and 24 months, respectively. HBA1C decreased significantly by a mean of 0.72% (P = 0.0001) and 0.75% (P = 0.010) and 11.5% and 12.8% were at HBA1C goal at 12 and 24 months, respectively. This study is limited by its retrospective and observational study design. CONCLUSIONS: Colesevelam treatment in a real-world setting was associated with improvements in LDL-C and HBA1C through 24 months of follow-up.